alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › amyloid-related-imaging

amyloid-related-imaging

22 studies tagged amyloid-related-imaging, dated 2025-01-24 to 2026-10-20. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Amyloid PET Changes During Lecanemab Treatment in Patients With and Without Amyloid-related Imaging Abnormalities 2026-10-20
  2. Intracranial metastasis as a mimic of amyloid-related imaging abnormalities 2026-10-15
  3. Incidence, severity, and associated risk factors for amyloid-related imaging abnormalities in anti-amyloid monoclonal antibody therapy for early Alzheimer's disease: a systematic review and meta-analysis 2026-10-02

Studies

22 studies carry this tag.

Date range

2025 to 2026

Top journals

  • Journal of Alzheimer's disease : JAD 4
  • AJNR. American journal of neuroradiology 2
  • Alzheimer's & dementia : the journal of the Alzheimer's Association 2
  • Cureus 2
  • Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2

15 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Amyloid PET Changes During Lecanemab Treatment in Patients With and Without Amyloid-related Imaging Abnormalities

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Clinical nuclear medicine 2026-10-20 Treatments

    Lecanemab reduces cerebral amyloid-β burden in Alzheimer disease, but whether amyloid-related imaging abnormalities (ARIA) are associated with greater amyloid clearance remains unclear.

  2. Intracranial metastasis as a mimic of amyloid-related imaging abnormalities

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026-10-15 Treatments

    This report describes a 79-year-old woman with biomarker-confirmed Alzheimer's disease who developed progressive vasogenic edema initially interpreted as amyloid-related imaging abnormalities (ARIA) with edema during lecanemab therapy, but was ultimately found to have multifocal intracranial metastases from recurrent papillary thyroid carcinoma.

  3. Incidence, severity, and associated risk factors for amyloid-related imaging abnormalities in anti-amyloid monoclonal antibody therapy for early Alzheimer's disease: a systematic review and meta-analysis

    ✓ Peer-reviewed alzhub usefulness score 83 out of 100. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026-10-02 Treatments

    ARIA remains a significant safety concern in anti-amyloid mAb therapy, with incidence and severity influenced by genetic, neuroimaging, and treatment-related factors.

  4. Progressive Amyloid-Related Imaging Abnormalities After Discontinuation of Lecanemab in Early Alzheimer Disease in an APOE ε2/ε4 Carrier

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. European journal of neurology 2026-10-01 Treatments

    This case highlights that severe ARIA may progress beyond active treatment exposure and emphasizes the importance of continued MRI surveillance even after therapy cessation.

  5. Lower baseline cerebrospinal fluid amyloid-β 42 is associated with amyloid-related imaging abnormalities during real-world lecanemab treatment

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Alzheimer's disease : JAD 2026-09-15 Treatments

    Amyloid-related imaging abnormalities (ARIA) are a safety concern during lecanemab treatment for early Alzheimer's disease.

  6. Baseline Amyloid PET Centiloid Score and Risk of Amyloid-Related Imaging Abnormalities in Patients Treated With Lecanemab

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. AJNR. American journal of neuroradiology 2026-08-13 Treatments

    Baseline global Centiloid was not independently associated with ARIA in patients treated with lecanemab.

  7. Demographic and Clinical Characteristics of Patients Treated With Lecanemab Stratified by Amyloid-Related Imaging Abnormality Status

    ✓ Peer-reviewed alzhub usefulness score 66 out of 100. Cureus 2026-08-13 Treatments

    In this real-world cohort of patients treated with lecanemab, ARIAs occurred in nearly one-third of patients.

  8. Volume change with gantenerumab: Impact of amyloid-related imaging abnormalities and amyloid removal

    ✓ Peer-reviewed alzhub usefulness score 75 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2026-08-01 Treatments

    ARIA are not associated with long-term parenchymal reduction; rather, they are linked to a fluid shift from the external space to the ventricles.

  9. Spectrum of amyloid-related imaging abnormalities associated with aducanumab treatment: a case series report

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. BMC neurology 2026-07-30 Treatments

    These illustrative cases provide learnings into the nature and factors associated with ARIA that can increase knowledge for clinicians and trialists regarding the varied radiographic and clinical presentations and evolution of ARIA.

  10. Amyloid-related imaging abnormalities after immunotherapy: How might brain microvascular basement membrane components be involved?

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of Alzheimer's disease : JAD 2026-07-11 Treatments

    Basement membrane components are integral to the physiologic function of cerebral microvessels.

  11. Comparative risk of amyloid-related imaging abnormalities with anti-amyloid-β monoclonal antibodies: A systematic review and penalized likelihood network meta-analysis of randomized trials

    ✓ Peer-reviewed alzhub usefulness score 88 out of 100. Journal of Alzheimer's disease : JAD 2026-07-11 Treatments

    BackgroundAnti-amyloid-β monoclonal antibodies represent a new class of disease-modifying therapies for Alzheimer's disease (AD).

  12. Reduced diffusion associated with amyloid-related imaging abnormalities in three patients treated with donanemab

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Neurocase 2026-07-02 Treatments

    Amyloid-related imaging abnormalities (ARIA) with edema (ARIA-E) and with hemorrhage (ARIA-H) are common adverse effects of amyloid-targeting therapies (ATT), characterized on MRI by T2/fluid-attenuated inversion recovery (FLAIR) hyperintensities and susceptibility-sensitive hypointensities, respectively.

  13. A Severe Symptomatic Case of Amyloid-Related Imaging Abnormalities After Donanemab Infusion

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Cureus 2026-05-17 Treatments

    Amyloid-related imaging abnormalities (ARIA) are known complications of anti-amyloid monoclonal antibody therapy for Alzheimer's disease.

  14. Relationship of Inferior Frontal Sulcal Hyperintensities with Amyloid-Related Imaging Abnormalities

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. AJNR. American journal of neuroradiology 2026-05-07 Treatments

    IFSH was higher among dementia patients on anti-amyloid therapy with ARIA than among their non-ARIA counterparts.

  15. MRI evaluation of cerebral perivascular spaces predicts amyloid-related imaging abnormalities risk in preclinical Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. Frontiers in dementia 2026-04-09 Treatments

    These results support the use of quantitative measurements of PVS in addition to WMH and microhemorrhages to assist clinicians in estimating an individual's risk of ARIA.

  16. Drug-Induced Amyloid-Related Imaging Abnormalities: A Neurovascular Perspective on Risk Assessment

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Pharmaceuticals (Basel, Switzerland) 2026-04-03 Treatments

    A more tailored patient selection and monitoring strategies may ultimately improve real-world outcomes and optimize resources in the era of AAT.

  17. Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2026-04-01 Treatments

    In 2011, a workgroup of the Alzheimer's Association Research Roundtable introduced recommendations for detecting and monitoring amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease (AD) clinical trials.

  18. Spontaneous and Drug-Induced Amyloid-Related Imaging Abnormalities: Overlaps, Divergences, and Clinical Implications Across a Continuum Between Alzheimer's Disease and Cerebral Amyloid Angiopathy

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Biomolecules 2026-01-05 Treatments

    Understanding the continuum between sARIA and dARIA is crucial for improving diagnostic criteria, risk stratification, and therapeutic approaches.

  19. Severe symptomatic amyloid-related imaging abnormalities in Alzheimer's disease: Two case reports and systematic review of reported cases

    ✓ Peer-reviewed alzhub usefulness score 79 out of 100. Journal of Alzheimer's disease : JAD 2025-12-12 Treatments

    BackgroundAmyloid-related imaging abnormalities (ARIA) are a recognized complication of anti-amyloid monoclonal antibodies for Alzheimer's disease (AD).

  20. MRI protocols and sequences for amyloid-related imaging abnormalities monitoring in Alzheimer's disease patients treated with monoclonal antibodies

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Current opinion in neurology 2025-06-04 Treatments

    This review provides an updated overview of amyloid-related imaging abnormalities (ARIA) associated with antiamyloid monoclonal antibodies (mAbs) in Alzheimer's disease (AD).

  21. Plasma Biomarkers for Cerebral Amyloid Angiopathy and Implications for Amyloid-Related Imaging Abnormalities: A Comprehensive Review

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of clinical medicine 2025-02-07 Treatments

    Anti-amyloid therapies (AATs) are increasingly being recognized as promising treatment options for Alzheimer's disease (AD).

  22. [Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer's Disease: Expert Recommendation for Standard MRI Protocol]

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of the Korean Society of Radiology 2025-01-24 Treatments

    The introduction of anti-amyloid therapies for Alzheimer's disease (AD), such as lecanemab (Lequembi ® ), which was recently approved in Korea, necessitates careful monitoring for amyloid-related imaging abnormalities (ARIA) using brain MRI.

All topic tags with their study counts